(Q46047228)

English

Predictors of unsuccessful mobilization with granulocyte colony-stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation

scientific article published on 21 February 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

Predictors of unsuccessful mobilization with granulocyte colony-stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

author name string

Signy Chow

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

Alejandro Lazo-Langner

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

George Ormond

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

Kang Howson-Jan

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

Anargyros Xenocostas

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

publication date

21 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

Journal of Clinical Apheresis

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

28

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

285-292

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Defining a Therapeutic Dose of Peripheral Blood Stem Cells

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Advances in mobilization for the optimization of autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

The bicyclam AMD3100 story

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

A simulation study of the number of events per variable in logistic regression analysis

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Cytokines and hematopoietic stem cell mobilization

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Can every patient be mobilized?

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FJCA.21252

21 January 2018

Identifiers

10.1002/JCA.21252

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23426584

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46047228&oldid=2089365814"